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Abstract
Background: Multipotent human mesenchymal stromal cells (hMSCs) are considered as promising biological tools for
regenerative medicine. Their antibody-based isolation relies on the identification of reliable cell surface markers.
Methodology/Principal Findings: To obtain a comprehensive view of the cell surface proteome of bone marrow-derived
hMSCs, we have developed an analytical pipeline relying on cell surface biotinylation of intact cells using cell impermeable,
cleavable sulfo-NHS-SS-biotin to enrich the plasma membrane proteins and mass spectrometry for identification with
extremely high confidence. Among the 888 proteins identified, we found <200 bona fide plasma membrane proteins
including 33 cell adhesion molecules and 26 signaling receptors. In total 41 CD markers including 5 novel ones (CD97,
CD112, CD239, CD276, and CD316) were identified. The CD markers are distributed homogenously within plastic-adherent
hMSC populations and their expression is modulated during the process of adipogenesis or osteogenesis. Moreover, our in
silico analysis revealed a significant difference between the cell surface proteome of hMSCs and that of human embryonic
stem cells reported previously.
Conclusions/Significance: Collectively, our analytical methods not only provide a basis for further studies of mechanisms
maintaining the multipotency of hMSCs within their niches and triggering their differentiation after signaling, but also a
toolbox for a refined antibody-based identification of hMSC populations from different tissues and their isolation for
therapeutic intervention.
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Introduction
Multipotent human mesenchymal stromal cells (hMSCs) [1],
initially described as colony-forming unit-fibroblasts [2,3], are
non-hematopoietic progenitors found in many tissues such as bone
marrow, umbilical cord blood, adipose tissues [4], dermis, muscles
[5], and placenta [6]. They are self-renewing cells that can
differentiate into a variety of cell types including osteoblasts,
chondrocytes, and adipocytes [7,8] and possibly neuron-like cells
[9,10], hepatocytes [11], or pancreatic-like cells [12]. Due to their
multi-lineage differentiation potential and their ability to migrate
to injured tissues [13], hMSCs are considered as promising
candidates for tissue engineering and regenerative medicine. Their
properties to suppress responses linked with immunity [14] or
inflammation [15,16,17] is also an advantage for clinical
applications. Beside ethical issues, pluripotent embryonic stem
cells (ESCs) have also these abilities and could also be considered
for therapeutic intervention. However, donor-derived tumors have
been observed after ESC transplantation [18].
Bone marrow-derived hMSCs have been isolated based on their
ability to adhere onto plastic surfaces [19]. These plastic adherent
cells can easily be expanded ex vivo while maintaining their
undifferentiated phenotype and gene expression profile during
long-term expansion [20]. However, some particular markers (e.g.
CD133 (prominin-1)) can be lost [21], possibly due to methods
used for either their isolation or propagation in culture [22,23,24].
Until now, no reliable cell surface markers have been described in
freshly isolated hMSCs.
It has always been difficult to identify membrane proteins by
mass spectrometry (MS), in particular plasma membrane proteins
that can be used as cell surface markers [25,26]. Different methods
have been applied to enrich membrane proteins, in particular
cellular fractionation [27,28]. However, the complexity of the
resulting proteome including quantitative proteomic analysis of
hMSCs undergoing differentiation towards distinct cell lineages
[27,28] is usually underestimated due to abundant contaminants,
and therefore a comprehensive understanding of the cell surface
proteome is limited [29].
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20399Here, we have combined cell biological, biochemical and
analytical methods allowing us to present the most comprehensive
cell surface proteome of hMSCs available to date. This data set can
be used to solve basic questions concerning the molecular and cellular
biology of hMSCs and their applications in regenerative medicine.
Results
Protein isolation and identification
Several methods have been used to reveal a cell surface signature
of hMSCs; first, cellular fractionation (purification of microsomal
membranes) followed or not by 1D-gel and MS-based identification
[27,28] and second, 2D-gel analysis using intact cells and MS-based
identification [30,31,32]. To identify bona fide cell surface proteins,
we have chosen a different approach relying on the biotinylation of
intact cells using cell impermeable, cleavable sulfo-NHS-SS-biotin.
After harvesting of the cells, the biotinylated proteins were purified
on streptavidin-beads. Upon reduction, the biotinylated proteins
werereleased from the beads and their adsorbed contaminants.The
eluted material was further fractionated by 1D-PAGE and, after in
gel-trypsinization, the 24 slices of the lanes were analyzed by LC-
MS/MS. The data from the LC-MS/MS analysis gave rise to a
unique data setof888 proteins.Thedata setrepresents proteinsthat
were identified with at least two sequenced peptides detected with
high mass accuracy. Functional classification of the proteins
according to the Gene Ontology database and literature surveys
revealed 169 bona fide cell surface membrane proteins with one or
more transmembrane domains or with a GPI anchor (Figure 1 and
Table S1). Because our proteomic analysis was performed using
pooled cells from different donors, 32 different alleles of the major
histocompatibility complex (MHC) class I (HLA-A, HLA-B, and
HLA-C) and MHC class 2 proteins were also identified. In addition,
we identified 18 secreted and 14 intracellular proteins, which are
potentially associated with ecto or cytoplasmic domains of these cell
surface membrane proteins. Thus, our analysis identifies with high
confidence <200 integral- and soluble proteins potentially associ-
ated with the plasma membrane that may regulate hMSC fate.
Characterization of hMSC cell surface proteins
Classification of the <200 plasma membrane-associated
proteins revealed several classes (Figure 1 and Table S1). Among
these proteins, a large set comprised 33 proteins involved in cell
adhesion like integrin chains a 1, 2, 3, 5, 7, 8, 11, V, b 1, 3, 5,
cadherins 2, 11, 13, and some adhesion molecules of the
immunoglobulin superfamily (e.g. CD54, CD106, and CD316).
Our analysis also revealed another large set of 26 proteins
comprising receptors involved in cell signaling such as PDGF-
receptor b, EGF-receptor, TGF b–receptor, TNF-receptor 6,
ephrin receptors, etc. In addition, we identified a panel of 21
transporters (e.g. solute carriers (1A5, 3A2, 7A5, 44A1, and 44A2)
and ATPases (1A1, 1B1, 1B3, 2B1, 2B4, and 11c)), groups of 13
ubiquitously expressed receptors (e.g. Transferrin receptor,
Anthrax toxin receptors 1 and 2, and Atrial natriuretic peptide
receptors), 11 enzymes like the metalloproteases 10 and 14, or
groups of tetraspanin and GPI-anchored proteins like the Thy-1
membrane protein. Secreted proteins most likely bound to the cell
surface of hMSCs could also be identified, in particular several
types of collagen, several lectins (galectins), or protease inhibitors
(serpins). Finally, our data revealed intracellular proteins poten-
tially associated with plasma membrane proteins via LIM domains
or proteins known to interact with cell adhesion molecules like
catenins binding to cadherins.
In our analysis we detected 41 predefined CD markers (Table 1
and Table S2). Thirty-one of these were already known as hMSC-
related antigens. The presence of 5 CD markers (CD98, CD99,
CD155, CD304, and CD325) at the hMSC surface was not firmly
established. Therefore, our analysis confirms the expression of
these CD markers. Interestingly, we also identified 5 CD markers
(CD97, CD112, CD239, CD276, and CD316) that have never
been reported to be expressed on the surface of hMSCs before.
The MS-based proteomic identifications were confirmed by
flow cytometry using a panel of specific antibodies recognizing
some of the CD markers identified by MS. Our analysis
demonstrated that the expanded, plastic-adherent hMSCs were
positive for a number of surface markers (Figure 2). During all cell
passages, the hMSCs were positive for the hMSC-associated CD
markers CD29, CD44, CD73, CD90, CD105, CD146, and
CD166, and negative for the hematopoietic markers CD14,
CD34, and CD45 as well as CD133 as previously reported [33]. In
addition, the hMSCs were positive for a panel of other surface
markers like CD54, CD56, CD61, CD63, CD71, CD97, CD98,
CD99, CD106, CD112, CD155, CD276 and CD304 in
agreement with the MS data (except for CD56) (Figure 2,
Table 1, and Table S2). Furthermore, CD325 expression was
confirmed by western blot analysis using total cell extracts from
hMSCs (data not shown).
Cell surface proteomes of adult mesenchymal stromal
cells and embryonic stem cells
Our comprehensive analysis of the cell surface proteome of
adult hMSCs allowed us to already establish with high confidence
similarities and differences/changes in cell surface proteomes of
different cell types. Of particular interest is the proteomic surface
profile of hESCs, which comprises 242 membrane proteins
identified thus far [34]. This comparison showed that surprisingly
hMSCs and hESCs have only 74 proteins in common, whereas 97
and 168 proteins are unique for hMSCs and hESCs, respectively
(Figure 3A and Table S3). Among these 74 common proteins,
adhesion molecules, signaling receptors, and transporters are the
most representative when compared to the total number of surface
membrane proteins identified in hMSCs and hESCs (Figures 1
and 3B). Only 16 adhesion molecules (incl. 8 integrins (a 1, 2, 3, 5,
7, V, and b 1 and 5 chains)) among the 33 cell adhesion molecules
identified on hMSCs were found on hESCs, thus suggesting that
the other unique cell adhesion molecules could be considered as
important molecules for specifying the proper niches of the
corresponding stem cells. The same remark could be made for the
proteoglycans detected at the cell surface of hMSCs and hESCs.
Only 10 out of the 26 signaling receptors detected on hMSCs were
found at the surface of hESCs such as EGF receptor, Ephrin type
A receptor 2, or Ephrin type B receptor 4, thereby suggesting that
the other signaling receptors are important for maintaining the
stemness or determining the fate of hMSCs or hESCs. Finally, it is
interesting to note that hMSCs and hESCs also express different
CD markers (Table 1). Among the 41 hMSC CD markers, 16 of
them (CD13, 47, 54, 61, etc.) were only detected on hMSCs and
not on hESCs.
Modifications of the hMSC cell surface proteome during
adipogenesis and osteogenesis
The hMSCs were differentiated toward the osteogenic or the
adipocytic lineages using classical differentiation cocktails. After
differentiation, modifications of the cell surface proteome, more
precisely the CD markers, were monitored by flow cytometry and
immunocytochemistry. These analyses showed that the expression
of a panel of markers was changed (Figure 4). CD90, CD97,
CD98, CD105, and CD155 were downregulated in both
The hMSC Cell Surface Proteome
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CD166 were upregulated in both cell types after 2 weeks of
differentiation. We noticed that CD97 expression increased during
the first week of differentiation towards osteoblasts but decreased
drastically when osteoblasts were mature. The remaining markers,
CD9, CD29, CD44, CD54, CD56, CD61, CD71, CD99, CD106,
CD146, CD276, and CD304 had different expression patterns
during adipogenesis and osteogenesis, respectively, whereas the
expression of the negative markers, CD14, CD34, CD45, and
CD133, did not change considerably as they were already not
detected on hMSCs (Figure 2).
Discussion
This study identifying <200 bona fide cell surface proteins
represents to our knowledge the most comprehensive cell surface
proteome of plastic-adherent hMSCs available to date. Our study
also highlighted with high confidence and good sequence coverage
5 new CD markers among the 41 identified, and how they change
in expression after differentiation into adipocytes or osteoblasts.
Thus, our data can be used for further isolation of hMSCs from
bone marrow or other tissues and for monitoring changes in the
cell surface proteome during the differentiation of hMSCs towards
different cell lineages.
A large majority of the proteins identified in our analysis have
never been reported to be present at the surface of hMSCs. This is
most likely due to the limits of the methods used previously to
isolate hMSCs, to purify membrane proteins or to identify cell
surface proteins by MS. For example, several studies have used cell
fractionation to purify microsomal membranes, which include not
only plasma membranes but also many other intracellular
membrane bounded compartments. For instance, Foster et al.
who purified membranes on density gradients found only <75
bona fide cell surface proteins among the 463 proteins identified
[27]. Similar analysis with total membranes led to the identifica-
tion of <100 bona fide cell surface proteins among the 707 proteins
identified [28]. Other proteomic analyses have been based on
classical 2D-gel fractionation of total proteins [30,31,32], a
method that is not optimal for the fractionation of high molecular
weight membrane proteins, which do not focus well. One study
included the labeling of intact cells with impermeable fluorescent
dyes prior to 2D-gel analysis to identify cell surface proteins.
However, this method had a much lower sensitivity than the non-
gel approach performed in the same study [28]. In order to reduce
the complexity of the proteome, we have chosen to use
biotinylation of surface proteins followed by streptavidin affinity
enrichment, as this method has previously been used to identify
plasma membrane proteins and can be adapted for proteomic
approaches [35,36,37]. For example, Gu et al. have identified
plasma membrane proteins from murine ESCs using biotinylation
[35]. In addition, we have used cleavable reagents allowing the
release of biotinylated proteins while keeping many proteins non-
specifically adsorbed onto the support. In addition, we have
chosen well-defined culture conditions maintaining as much as
possible the multipotency properties of plastic-adherent hMSCs
[33]. Thus, our proteomic analysis identifying 201 bona fide plasma
membrane proteins is therefore at least two times more
comprehensive than previous studies, in particular when cell
adhesion molecules, signaling receptors, and CD markers are
considered.
Our proteomic analysis of cell surface proteins to a large extent
confirmed by flow cytometry, identifies with high confidence a
panel of 5 new markers of plastic adherent hMSCs that could be
used for their prospective isolation from tissues. Among the
identified proteins are several integrin chains (e.g. a 7, 8, and 11),
and CD antigens like CD97, CD98, CD99, CD112, CD155,
CD239, CD276, CD304, CD316, and CD325. Some of these
markers were identified earlier in a few reports but their
significance was still questioned [27,28,38], and the expression of
CD97, CD112, CD239 CD276, and CD316 on hMSCs was not
previously reported. Thus, our study resolves these ambiguities.
These proteins may have an important role in hMSC biology. For
example, the solute carrier, CD98, has a possible role in amino
acid transport necessary for cell growth, and several proteins may
be involved in cell adhesion such as CD97, CD99, CD112
(poliovirus receptor-related protein 2), CD155 (poliovirus recep-
tor), and CD325 (cadherin-2) [39,40]. Some others may be
involved either in cell proliferation (e.g. CD276) or cell
Figure 1. Cell surface proteome of human mesenchymal stromal cells. Distribution and functional clustering of identified proteins.
doi:10.1371/journal.pone.0020399.g001
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Marker
b,c MS Flow cytometry Literature
a
Protein
expressed
Peptide
numbers
Percentage
coverage
Protein
expressed
CD9: Tetraspanin–29 + 10 31.14 ++
CD13
b: Aminopeptidase N + 74 29.99 nd +
CD14: LPS receptor 222 2 2
CD29: Integrin b-1 + 145 40.48 ++
CD34: Hematopoietic progenitor cell antigen 222 2 2
CD44: Phagocyte glycoprotein 1 + 139 13.61 ++
CD45: Leukocyte common antigen 222 2 2
CD46: Membrane cofactor protein + 6 8.67 nd +
CD47
b: Leukocyte surface antigen + 4 5.88 nd +
CD49a: Integrin a-1 + 39 16.96 nd +
CD49b: Integrin a-2 + 3 2.96 nd +
CD49c: Integrin a-3 + 18 10.23 nd +
CD49e: Integrin a-5 + 31 13.25 nd +
CD51: Integrin a-V + 45 29.01 nd +
CD54
b: Intercellular adhesion molecule 1 (ICAM1) + 5 8.27 ++ /2
CD56: Neural cell adhesion molecule (NCAM) 222 ++ /2
CD59: Protectin + 12 25.78 nd +
CD61
b: Integrin b-3 + 4 7.74 (+) +/2
CD63: LAMP-3 + 9 7.56 ++
CD71: Transferrin receptor + 21 25.53 ++
CD73
b: Ecto-59-nucleotidase + 24 29.44 ++
CD81: Tetraspanin-28 + 47 33.05 nd +
CD90: Thy-1 + 35 24.84 ++
CD95
b: Fas antigen + 17 27.76 nd +
CD97
b: Leukocyte antigen CD97 + 10 9.58 + nd
CD98: Solute carrier family 3 (SLC3A2) + 98 52.55 ++
CD99
b: E2 antigen + 21 15.14 ++
CD105
b: Endoglin + 52 34.65 ++
CD106
b: Vascular cell adhesion molecule-1 (VCAM1) + 29 16.78 +/2 +/2
CD109
b: Platelet–specific Gov antigen + 28 13.91 nd
CD112: Polio virus receptor related 2 protein + 14 14.13 (+)n d
CD133: Prominin-1 222 2 2
CD140b
b: Platelet derived growth factor + 94 29.57 nd +
CD146: Melanoma cell adhesion molecule (MCAM) + 68 47.21 ++
CD147: Basigin + 56 25.71 nd +
CD151
b: Tetraspanin-24 + 49 20.95 nd +
CD155
b: Polio virus receptor + 17 18.71 ++
CD166: Activated leukocyte cell adhesion molecule (ALCAM) + 92 48.54 ++
CD172a
b: Signal regulatory protein alpha + 19 21.27 nd +
CD239: Basal cell adhesion molecule (BCAM) + 10 16.4 nd nd
CD248: Endosialin + 19 9.78 nd +
CD276: B7 homolog 3 + 20 26.4 + nd
CD304
b: Neuropilin-1 + 7 4.98 ++
CD316: Immunoglobulin superfamily, member 8 + 4 10.28 nd nd
CD325: Cadherin 2 + 12 15.67 nd nd (mRNA
positive)
The hMSC Cell Surface Proteome
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20399differentiation like the receptor CD304 (neuropilin-1) [28,41].
Finally, CD316 interacts with the tetraspanins CD9 and CD81,
which are also known hMSC markers [42,43,44]. However, our
analysis failed to identify few known markers of hMSCs like CD56
or CD133 although our flow cytometry data indicated that the
hMSCs were partially positive at least for CD56. It is known that
both CD56 and CD133 are expressed in freshly isolated hMSCs
and that their expression is rapidly down-regulated when hMSCs
are maintained in culture [21,42].
Among the different classes of cell surface proteins, the two
major classes consisting of cell adhesion molecules and signaling
receptors are more than likely playing a major role in hMSC
biology, in particular for maintaining their stemness feature or
triggering their differentiation towards different lineages. Accord-
ing to our analysis, hMSCs express on their surface 7 a and 3 b
integrin chains, thereby providing a wide spectrum of possible
integrin receptors, 3 cadherins (together with a, b and d catenins
for signaling) and other types of CD markers associated with cell-
+ and 2 refer to the presence or absence of a given marker, respectively.
+/2 refers to heterogenous expression within an hMSC population.
nd; not determined.
aReferences for the published results are presented in Table S2.
bCD markers unique for hMSCs compared with those for hESCs published by Dormeyer et al. [34].
cCD markers unique for hESCs: CD30, CD40, CD49f, CD74, CD133, CD200, CD266, CD271 and CD320 [34].
doi:10.1371/journal.pone.0020399.t001
Table 1. Cont.
Figure 2. Flow cytometric analysis of hMSC surface CD markers. Cells were harvested and labeled with fluorescence-conjugated antibodies
recognizing cell surface markers. Black: isotype control; blue: Ab against surface markers. At least three independent experiments were performed.
Shown are representative flow cytometry histograms.
doi:10.1371/journal.pone.0020399.g002
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immunoglobulin superfamily. Some of these cell adhesion
molecules such as integrins a 1, 2, 3, 5, 7, and V, and b 1, 5 as
well as CD44 and CD166 were also detected at the surface of
hESCs whereas some others such as integrins a 8 and 11, and b 3,
cadherins 2, 11, 13, CD97 or CD99 were found unique to hMSCs.
A similar observation could be made for proteoglycans and
secreted proteins such as collagens, galectins or fibronectin, which
specify the nature of extracellular matrixes. This may indicate that
a combinatorial use of adhesion molecules may be required for
maintaining stem cells in a given niche. However, this possible
interpretation waits for a more comprehensive understanding of
the cell surface proteome of hESCs, for which our analysis of
hMSCs may provide a new basis.
Roughly, 25 signaling molecules are present at the cell surface of
hMSCs such as EGF receptor, ephrin type-B receptor 4, and
ephrin type-A receptor 2 also detected on hESCs. TGF-b receptor
type-1, PDGF receptor b, tyrosine-protein phosphatase non-
receptor type substrate 1, and tumor necrosis factor receptor
superfamily member 6 would be unique to hMSCs. Some of these
receptors may be important for triggering the differentiation of
hMSCs. EGF signaling is known to be important for triggering
osteogenesis [45], and PDGF signaling is important for the
chemotaxis of MSCs and osteoblasts during bone remodeling [46].
Figure 3. Comparison of hMSC and hESC cell surface protein profiles. A. Comparison of the membrane protein profiles of hMSCs (our study)
and hESCs according to [34]. The diagram shows unique and common membrane proteins of hESCs (left) and hMSCs (right). B. Distribution and
functional clustering of common membrane proteins between hESCs and hMSCs.
doi:10.1371/journal.pone.0020399.g003
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clastogenesis, and its expression in MSCs from myeloma patients
and in bone cells in myelomatous bones is lower than in healthy
counterparts [47]. This receptor also regulates the embryonic stem
cell differentiation [48]. Therefore, it is likely that the other
signaling molecules detected in our proteomic screen of cell
surface proteins of hMSCs play an important function in their
biology. At the same time, some ‘‘stemness’’ genes might be
downregulated during differentiation. Potential new stemness
genes are CD97 and CD155. These genes were downregulated
during both adipogenesis and osteogenesis in addition to their
unique expression on hMSCs when compared to hESCs. CD97
with adhesive properties belongs to the epidermal growth factor-
transmembrane 7 family and is known to play an important role in
tumor differentiation, invasiveness, and metastasis by binding to its
cellular ligand CD55 [49,50,51]. It has also been involved in
leukocyte trafficking and function [52]. CD155, which serves as a
ligand for CD226 and CD96 receptors is also overexpressed in
tumor cell lines and primary tumors and promotes their invasion
and migration [40,53]. We also confirmed the downregulation of
CD90, CD98, and CD105 as shown previously [28,54].
Furthermore, we show the downregulation of a panel of markers
(CD29, CD44, CD61, CD71, CD99, CD106, CD276, and
CD304) during osteogenesis and downregulation of CD9 and
CD54 during adipogenesis. It was also previously shown, that
CD44, CD81, and CD166 are downregulated during chondro-
genic differentiation [54], CD106 during osteogenic differentiation
[55], and that the expression of some others is downregulated
during several differentiation processes, for example integrin a 11
during osteogenic, adipogenic and chondrogenic differentiation,
and CD325 during osteogenic and adipogenic differentiation [44].
We did not observe a complete loss of these markers, probably due
Figure 4. Differentiation of hMSCs towards the adipogenic or osteogenic lineage. A+B. Immunocytochemistry after 1 week of
differentiation. Nuclei were visualized with DAPI. C+D. Flow cytometry after 2 weeks. The change in the mean fluorescence intensity (MFI) before and
after differentiation was calculated taking hMSCs as a reference. At least three independent experiments were performed. Black: hMSCs; red:
differentiated cells. Shown are representative stainings.
doi:10.1371/journal.pone.0020399.g004
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osteoblasts or adipocytes do not allow the differentiation of the
total cell population.
Thus, our analysis of the cell surface proteome of hMSCs may
provide key insights into their biology. It also provides a panel of
membrane proteins, which can represent the basis for the
definition of an hMSC signature that can be used for the
identification and the isolation of hMSCs for regenerative
medicine.
Materials and Methods
Isolation and culture of plastic–adherent hMSCs
Bone marrow aspirates were collected from healthy donors after
verbal and written consent. The study was approved by the local
ethics committee (Ethikkommission an der Technischen Universi-
ta ¨t Dresden, Ethic board no. EK263122004). hMSCs were
isolated and cultured as previously described [33]. Briefly, 5–
7 ml of bone marrow aspirate was diluted 1:5 in phosphate-
buffered saline (PBS) containing 0.5% human serum albumin
(HSA; Braun, Melsungen, Germany). A 20-ml aliquot was layered
over a Percoll solution (d=1.073 g/ml; Biochrom, Berlin,
Germany) and centrifuged at 900 g for 30 min at room
temperature. Mononuclear cells at the interface were recovered,
pressed through a 100 mm Nylon cell strainer (BD Biosciences,
Heidelberg, Germany) and washed twice in PBS–HSA solution.
All cells were seeded into 75-cm
2 flasks containing MSC medium,
consisting of Dulbecco’s modified Eagle medium (DMEM)-low
glucose (Invitrogen, Darmstadt, Germany) supplemented with
10 mM L-glutamine and 10% fetal calf serum (FCS) (Biochrom).
hMSC cultures were grown at 37uC under a humidified 5% CO2
atmosphere. Nonadherent cells were removed after 24 h by
washing with PBS–HSA solution. The medium was changed every
4 days and after 2 weeks the cultures were 90% confluent. hMSCs
were recovered using trypsin (Invitrogen) and replated at a density
of 5–6610
3 cells per cm
2 of surface area as passage 1 cells.
Subsequently cells were kept in culture for up to 8 passages and
tested routinely for the presence of MSC-associated surface
molecules like CD29, CD44, CD73, CD90, and CD105, and
the absence of the hematopoietic markers CD34 and CD45.
Under such conditions, hMSCs maintain their multilineage
capacity to differentiate into osteoblasts, chondrocytes, and
adipocytes [33].
For the differentiation assays, cells were seeded into 24-well
plates at a density of 1610
4 cells per well. Next day the initial
growth medium was replaced with medium for either adipogenic
or osteogenic differentiation. The adipogenic medium consisted of
DMEM-low glucose supplemented with 10 mM L-glutamine,
10% FCS, 500 mM isobutyl-methylxanthine, 1 mM dexametha-
sone, 10 mM insulin, and 200 mM indomethacin whereas the
osteogenic medium was supplemented with 10 mM L-glutamine,
10% FCS, 0.1 mM dexamethasone, 200 mM ascorbic acid, and
10 mM b-glycerophosphate (all supplements were from Sigma-
Aldrich, Munich, Germany). The level of adipogenic differentia-
tion was tested by Oil red O staining of intracellular lipid droplets,
and osteogenic differentiation was tested by Alizarin red S staining
as described previously [56] (results not shown).
Biotinylation of cell surface proteins
hMSCs (,10
7 cells from different donors) were rinsed three
times with PBS supplemented with 1 mM CaCl2 and 0.5 mM
MgCl2 (Ca/Mg-PBS), and incubated with 0.5 mg/ml EZ-Link
Sulfo-NHS-SS-biotin (Thermo Fisher Scientific, Bonn, Germany)
for 1 h at 4uC on a rocking platform. After washing three times
with Ca/Mg-PBS, the cells were incubated with 20 mM glycine in
Ca/Mg-PBS for 10 min to quench the residual biotin followed by
three washes with Ca/Mg-PBS. The cells were harvested,
centrifuged for 5 min at 500 g, and then lysed in 250 ml ice-cold
PBS containing 0.1% SDS, 1% Triton X-100, and Protease
Inhibitor Mix (Serva Electrophoresis, Heidelberg, Germany). This
extract was diluted four-fold with Ca/Mg-PBS and incubated with
20 ml streptavidine-agarose beads for 2 h at 4uC while rotating.
The beads were washed five times with Ca/Mg-PBS containing
0.1% Triton X-100 and five times with five-fold diluted Ca/Mg-
PBS containing 0.1% Triton X-100. Then the beads were
incubated with elution buffer containing 50 mM 2-mercaptoetha-
nesulfonate in Ca/Mg-PBS supplemented with 0.1% Triton X-
100 for 2630 min at RT. The released material was transferred
into an Ultrafree-MC spin filter (0.45 mm) (Millipore, Schwalbach,
Germany) and centrifuged in a table-top centrifuge. The proteins
in the flow through were precipitated with 10% trichloroacetic
acid, and the pellet obtained after centrifugation was dissolved in
Laemmli buffer.
Sample preparation, mass spectrometric analysis and
protein identification
The biotinylated proteins were fractionated onto a Tris-glycine
PAGE gel and stained with Coomassie G-250. The lanes were cut
into 24 slices. The embedded proteins were reduced with
dithiothreitol, alkylated with iodoacetamide, digested overnight
with trypsin in a 1:50 ratio and subjected to LC-MS/MS analysis.
Peptides were separated on an EASY-nLC HPLC system
(Proxeon, Odense, Denmark) equipped with a fused silica
microcapillary C18 column (Proxeon, length 10 cm; inner
diameter 75 mm; particle size 3 mm, 100 A ˚ pore size. The gradient
used was: A, 0.1% formic acid; B, acetonitrile, 0.1% formic acid
with a final concentration of 80% B. Mass spectrometry analysis
was made on a LTQ Orbitrap XL mass spectrometer (Thermo
Fisher Scientific). The MS data were analyzed using the Proteome
Discoverer 1.0 software (Thermo Fisher Scientific). Mascot
(version 2.2.2) and the SwissProt database (SwissProt_56.9.fasta)
were used for interpretation of spectra applying the following
settings: the taxonomy was set to human and trypsin as the enzyme
allowing up to two missed cleavages. Precursor mass tolerance was
set to 10 ppm, fragment mass tolerance to 0.5 Da. As a static
modification carbamidomethylation (of Cysteine) was chosen and
as dynamic modifications deamidation (of Asparagine and
Glutamine) and oxidation (of Methionine). Protein hits were
filtered for a minimum of identified peptides of two with a
minimum score of 40, possessing either transmembrane domains
and known plasma membrane localization or a signaling sequence
and known lipid modification.
Flow cytometry
Flow cytometric analysis was performed on hMSCs harvested
by cell scraping or trypsin (Invitrogen) treatment. After washing
cells in ice-cold PBS containing 2% FCS, the appropriate
antibodies were added, and the stainings were performed in
50 ml cell suspension for 30 min at 4uC. The following antibodies
were used: CD9-PE (clone HI9a), CD90-Alexa700 (clone 5E10)
(both from BioLegend, Uithoorn, The Netherlands), CD14-APC
(clone 61D3), CD97-APC (clone VIM3b), CD99-PE (clone 3B2/
TA8), CD112-APC (clone R2.525) (all from eBioscience, San
Diego, CA, USA), CD29-PE (clone HUTS-21), CD34-FITC
(clone 581), CD44-PE (clone G44-26), CD45-APC (clone HI30),
CD54-Alexa488 (clone HA58), CD56-PE (clone B159), CD61-
FITC (clone VIPL2), CD71-FITC (clone M-A712), CD73-PE
The hMSC Cell Surface Proteome
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51-10C9), CD166-PE (clone 3A6), (all from BD Biosciences),
CD63-FITC (clone MEM-259) (from Acris Antibodies, Herford,
Germany), CD146-APC (clone 541-10B2), CD133-PE (clone
293C3) (both from Miltenyi Biotec, Bergisch Gladbach, Ger-
many), CD155-PE (clone 300907), CD276 (B7-H3)-Fluorescein
(clone 185504), and CD304 (neuropilin-1)-Fluorescein (clone
446921) (all from R&D Systems, Wiesbaden-Nordenstadt, Ger-
many). CD105-APC (clone SN6) was purchased from Invitrogen.
Mouse IgG1-Alexa Fluor 488 and mouse IgG1-Alexa Fluor 700
isotype controls were from eBioscience. Otherwise all isotype
controls were from BD Biosciences. Except for the stainings with
antibodies against CD61, CD71, and CD304, where the cells were
scraped off the culture plate, all data was acquired after
trypsinization of the cells. After washing with PBS containing
2% FCS, cells were acquired on an LSRII flow cytometer (BD
Biosciences). Instrument settings and gating strategies were
established using isotype controls. Data was analyzed using the
FlowJo software (Treestar, Ashland, OR, USA).
Immunocytochemistry
hMSCs, differentiated adipocytes and osteoblasts grown on
coverslips were cell-surface immunolabeled. Briefly, cells were
washed twice with PBS followed by ice-cold Ca/Mg-PBS, and
then incubated with fluorescence-conjugated antibodies diluted in
Ca/Mg-PBS for 1 h at 4uC. Labeled cells were washed twice with
PBS and fixed with 4% paraformaldehyde for 15 min at RT. After
quenching with 50 mM NH4Cl for 10 min, fixed cells were
washed with PBS and mounted in Mowiol (Merck, Darmstadt,
Germany) containing 4,6-diamidino-2-phenylindole (DAPI) for
counterstaining the nuclei. The resulting stainings were examined
using a Zeiss Axiovert 200 M fluorescence microscope.
Supporting Information
Table S1 List of hMSC cell surface proteins identified in this
study.
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